Skip to content
FDAMedicinesClass IIIOngoing

FDA recall 99330: Ascend Laboratories, LLC: Dabigatran etexilate Capsules and 1 more

FDA recall 99330 ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Status: Ongoing. What the FDA’s recall statuses mean (opens in a new tab)

Note from Recalls Watch, not agency text

Why it was recalled

Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
Text from FDA, unedited.

FDA classification: Class III. What the FDA’s classes mean (opens in a new tab)

The recalled product

Codes in the record. Click one to copy it.

  • Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7254-68.

    Lot or code
    Lot: 25141707, Exp 4/30/2027.
    FDA recall number
    D-0735-2026
    Quantity
    1,753 cartons
  • Dabigatran etexilate Capsules, 150 mg, 20-count carton (2x10), Rx only, Manufactured by: Alkem Laboratories, Mumbai, INDIA, Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, NDC 0904-7255-10.

    Lot or code
    Lot: 25141584, Exp 4/30/2027.
    FDA recall number
    D-0736-2026
    Quantity
    2,717 cartons

Distribution (FDA): USA Nationwide

Source

Issued by
U.S. Food and Drug Administration
Firm
Ascend Laboratories, LLC
Title
Composed by Recalls Watch from fields of the record; FDA records have no title.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Ascend Laboratories, LLC, Medicine: Dabigatran, Month: July 2026, Week 2026-W31. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published recall 99330 on July 29, 2026.

Other notices of Ascend Laboratories, LLC